- Samsung Bioepis, the joint venture between Biogen (NASDAQ:BIIB) and Samsung BioLogics, and Takeda Pharmaceutical Company (OTCPK:TKPHF) ink a strategic collaboration agreement to jointly fund and co-develop novel biologic therapies to treat diseases with high unmet need.
- The companies will begin working immediately on TAK-671 for the treatment of severe acute pancreatitis.
- The partnership will leverage Takeda's drug development know-how with Samsung Bioepis' biologics development platform. Financial terms are not disclosed.